Actavia Life Sciences, Inc. 是一家生物技術公司,致力於開發用於治療白血病和淋巴瘤疾病的療法。公司總部位於紐約州紐約市,目前擁有1名全職員工。該公司於2014年3月28日上市。公司致力於開發治療方法,以滿足急性骨髓性白血病(AML)及其他類型白血病和淋巴瘤尚未滿足的醫療需求。AML通常是一種老年人疾病。公司正在開發靶向LSD1基因的小分子藥物候選物,該基因控制著AML亞型發病機制的相關通路。其RASP-201是一種新型口服、選擇性可逆的賴氨酸特異性去甲基化酶(LSD1)抑制劑,該通路會阻斷細胞分化並導致AML預後不良。在AML小鼠模型中,口服RASP-201顯示出體內治療效果。其主要適應症為AML,該病可能在數週至數月內致命。
RASP stock price ended at $0 on 星期五, after dropping 100.00%
On the latest trading day Dec 26, 2025, the stock price of RASP fell by 100.00%, dropping from $0.00 to $0.00. During the session, the stock saw a volatility of NaN%, with prices oscillating between a daily low of $0.00 and a high of $0.00. On the latest trading day, the trading volume for RASP rose by 19.6K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 20.0K shares were traded, with a market value of approximately --.